QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Vanda Pharmaceuticals Inc. (VNDA)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
2

Do Nothing: fundamentalScore 2 is below the required floor of 3, and the 20-session average dollar volume of $4,895,995 is under the $5,000,000 liquidity floor, so no long entry is admitted; the chart is only a bounce-only read at a 52-week low — a pullback limit would be countertrend (price 3.88 below SMA50 4.70 with MACD -0.25, and below a declining SMA200 6.16 with SMA50 < SMA200 and no reclaim), and a breakout buy-stop above the settled 4.11 high yields only 0.94 R/R.

Analysis as of 2026-11-05· more than 2 trading days ago

Company overview

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for unmet medical needs. It offers HETLIOZ for non-24-hour sleep-wake disorders and Fanapt for schizophrenia. The company is also exploring new applications for these therapies and advancing other compounds for various conditions.

Fundamental

weak
Fundamental2
Weak fundamentals

Vanda's fundamentals are weak, with significant cash burn, legal risks, and a probable need for dilutive financing.

Cash-burning commercial-stage specialty pharma: trailing revenue near $229M at a 93% gross margin, but a $178M operating loss, about $110M of nine-month operating cash burn and a 47% drawdown in liquidity to $140.5M with no credit facility. Both DCF models return negative equity value, the Altman Z-Score sits in the distress zone, and a possible DOJ False Claims Act complaint plus an adverse HETLIOZ patent ruling add binary legal risk. Fanapt growth, the NEREUS and BYSANTI launches and FY2026 revenue guidance above $240M are real offsets, but a dilutive financing looks probable within a year - weak fundamentals with elevated risk, not a short-horizon buy.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is mixed, with some positive catalysts but overshadowed by legal and financial uncertainties.

Dominant driver is the announced 2026-10-27 positive Phase III NEREUS/tradipitant Study 3601 readout (product, material, the only in-window item the tape rewarded at +0.4/+0.5), partially offset by a mixed Q3 2026 print on 2026-10-28 and by the confirmed adverse HETLIOZ patent rulings of 2026-08-18 and 2026-09-25 that opened a generic-erosion path. The sentiment delta is a determinate improvement of roughly +0.18, from a net-negative baseline of about -0.11 (8 scored items) to a mildly positive scoring window of about +0.07 (16 scored items) that nonetheless lands near flat in absolute level, and a moderate red-flag cap applies on confirmed material adverse HETLIOZ patent litigation, with no forward-dated catalyst to lift the setup above that ceiling.

Technical

weak
Technical2
Downtrend persists

The stock remains in a downtrend, with no clear reversal signals and low liquidity.

Chart score 2 of 5 — bounce-only, not a bullish setup. VNDA at 3.88 is in a primary downtrend: price sits below the SMA20 (4.10), SMA50 (4.70) and SMA200 (6.16), and the entire MA stack is declining (the stock has fallen from ~9.6 in March 2026 to 3.88). ADX 29.68 confirms a still-strong residual downtrend even as it cools from 38.2. The only constructive evidence is short-term stabilization: RSI14 35.58 recovering from 26.67 on 2026-10-30, Williams %R -76.0 lifting off -94.4, MACD histogram flipping to +0.01 (line -0.25 vs signal -0.26), and four sessions basing between 3.64 and 3.95 with the 2026-11-04 close above that session's VWAP of 3.83. That is a bounce at a 52-week low, not a reversal: price has not reclaimed even the EMA9 (3.93), volume is unremarkable, and there is no bullish confirmation across trend plus momentum plus volume. Nothing here justifies a 1-15 day long. The trade is additionally blocked by Step 00 gates (fundamentalScore 2 < 3; avgDollarVolume20 $4.90M < $5M floor), so setupType is no_setup and the action is Do Nothing.

You’re looking at 2026-11-05 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.